• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鱼鳔核糖体生物发生因子 1 减少抑制头颈部鳞状细胞癌的肿瘤生长并使其对化疗敏感。

Pescadillo ribosomal biogenesis factor 1 reduction suppresses tumour growth and renders chemosensitivity of head and neck squamous cell carcinoma.

机构信息

Department of Otolaryngology-Head & Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China.

Anhui Medical University, Hefei, People's Republic of China.

出版信息

Cancer Med. 2023 Mar;12(5):5703-5717. doi: 10.1002/cam4.5315. Epub 2022 Oct 11.

DOI:10.1002/cam4.5315
PMID:36217758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10028059/
Abstract

BACKGROUND

As one of the most devastating cancers, head and neck squamous cell carcinoma (HNSCC) has a short survival time and poor prognosis. Pescadillo ribosomal biogenesis factor 1 (PES1) plays a critical role in the progression of numerous cancers. However, its role and underlying mechanisms in HNSCC remain unclear.

METHODS

A variety of bioinformatic approaches were used to identify the expressions, prognostic and diagnostic value of PES1 in HNSCC. qRT-PCR, immunofluorescence (IF) assay, western blotting and immunohistochemical (IHC) were used to evaluate the expression of PES1 in HNSCC cell lines and clinical tissues. PES1 was knocked down in TU177 and FaDu cells which have high PES1 expression. The effects of PES1 on cell proliferation and tumour growth in HNSCC were elevated by colony formation, CCK8 assays and tumorigenicity assay in nude mice. The effects on cisplatin (CDDP) sensitivity upon silencing of PES1 were assessed using a patient-derived xenograft (PDX) model.

RESULTS

PES1 expression was an independent prognostic factor for HNSCC and negatively associated with the overall survival rate. Silencing of PES1 reduces HNSCC cell proliferation and tumour growth. Moreover, PES1 inhibition significantly sensitises HNSCC cells to cisplatin. Furthermore, we found a PES1 has a high correlation with c-Myc and plays an essential role in the tumour immune microenvironment.

CONCLUSION

Our findings suggest that PES1 is associated with tumour growth and drug resistance and served as a potential cancer marker for diagnosis and a putative therapeutic target for HNSCC.

摘要

背景

作为最具破坏性的癌症之一,头颈部鳞状细胞癌(HNSCC)的存活时间短,预后差。Pescadillo 核糖体生物发生因子 1(PES1)在许多癌症的进展中起着关键作用。然而,其在 HNSCC 中的作用和潜在机制尚不清楚。

方法

使用多种生物信息学方法来鉴定 PES1 在 HNSCC 中的表达、预后和诊断价值。使用 qRT-PCR、免疫荧光(IF)检测、Western blot 和免疫组织化学(IHC)评估 PES1 在 HNSCC 细胞系和临床组织中的表达。在 PES1 高表达的 TU177 和 FaDu 细胞中敲低 PES1。在裸鼠中通过集落形成、CCK8 检测和致瘤性检测来提高 PES1 对 HNSCC 细胞增殖和肿瘤生长的影响。使用患者来源的异种移植(PDX)模型评估沉默 PES1 对顺铂(CDDP)敏感性的影响。

结果

PES1 表达是 HNSCC 的独立预后因素,与总生存率呈负相关。沉默 PES1 可降低 HNSCC 细胞的增殖和肿瘤生长。此外,PES1 抑制可显著增强 HNSCC 细胞对顺铂的敏感性。此外,我们发现 PES1 与 c-Myc 高度相关,在肿瘤免疫微环境中发挥重要作用。

结论

我们的研究结果表明,PES1 与肿瘤生长和耐药性相关,可作为潜在的癌症诊断标志物和 HNSCC 的潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea2f/10028059/9ae41a68fe2c/CAM4-12-5703-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea2f/10028059/3af4421d56d7/CAM4-12-5703-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea2f/10028059/63433d5f7d8f/CAM4-12-5703-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea2f/10028059/c5feb2cbab1d/CAM4-12-5703-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea2f/10028059/2223259848a1/CAM4-12-5703-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea2f/10028059/e8e8e3ce0c73/CAM4-12-5703-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea2f/10028059/9ae41a68fe2c/CAM4-12-5703-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea2f/10028059/3af4421d56d7/CAM4-12-5703-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea2f/10028059/63433d5f7d8f/CAM4-12-5703-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea2f/10028059/c5feb2cbab1d/CAM4-12-5703-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea2f/10028059/2223259848a1/CAM4-12-5703-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea2f/10028059/e8e8e3ce0c73/CAM4-12-5703-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea2f/10028059/9ae41a68fe2c/CAM4-12-5703-g006.jpg

相似文献

1
Pescadillo ribosomal biogenesis factor 1 reduction suppresses tumour growth and renders chemosensitivity of head and neck squamous cell carcinoma.鱼鳔核糖体生物发生因子 1 减少抑制头颈部鳞状细胞癌的肿瘤生长并使其对化疗敏感。
Cancer Med. 2023 Mar;12(5):5703-5717. doi: 10.1002/cam4.5315. Epub 2022 Oct 11.
2
PES1 is a biomarker of head and neck squamous cell carcinoma and is associated with the tumor microenvironment.PES1 是头颈部鳞状细胞癌的生物标志物,与肿瘤微环境相关。
Cancer Med. 2023 Jun;12(11):12622-12638. doi: 10.1002/cam4.5948. Epub 2023 Apr 19.
3
PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway.PES1 通过 PI3K/AKT 通路促进肝癌的增殖和肿瘤发生。
Life Sci. 2019 Feb 15;219:182-189. doi: 10.1016/j.lfs.2018.12.054. Epub 2019 Jan 8.
4
TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.TNFAIP2 通过 KEAP1/NRF2 信号通路赋予头颈部鳞状细胞癌对顺铂的耐药性。
J Exp Clin Cancer Res. 2023 Aug 1;42(1):190. doi: 10.1186/s13046-023-02775-1.
5
Integrative analyses of biomarkers and pathways for metformin reversing cisplatin resistance in head and neck squamous cell carcinoma cells.整合生物标志物和通路分析,探讨二甲双胍逆转头颈部鳞状细胞癌细胞顺铂耐药的作用机制。
Arch Oral Biol. 2023 Mar;147:105637. doi: 10.1016/j.archoralbio.2023.105637. Epub 2023 Feb 1.
6
PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.PI3K 抑制剂抑制头颈部鳞状细胞癌中 MYC 依赖性突变 p53 的功能获得。
Clin Cancer Res. 2020 Jun 15;26(12):2956-2971. doi: 10.1158/1078-0432.CCR-19-2485. Epub 2020 Jan 22.
7
Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.NRF2 信号轴的失调和表观遗传重编程促进头颈部鳞状细胞癌获得顺铂耐药性和转移。
Clin Cancer Res. 2023 Apr 3;29(7):1344-1359. doi: 10.1158/1078-0432.CCR-22-2747.
8
Resveratrol‑induced REG III expression enhances chemo‑ and radiosensitivity in head and neck cancer in xenograft mice.白藜芦醇诱导 REG III 表达增强异种移植小鼠头颈部癌的化疗和放疗敏感性。
Oncol Rep. 2019 Jul;42(1):436-442. doi: 10.3892/or.2019.7137. Epub 2019 Apr 25.
9
Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models.缺氧生物标志物在头颈癌肿瘤模型中的临床相关性及治疗预测能力
Mol Oncol. 2024 Aug;18(8):1885-1903. doi: 10.1002/1878-0261.13620. Epub 2024 Mar 1.
10
The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.Polo-like 激酶 1 抑制剂 onvansertib 是一种针对对头颈部鳞状细胞癌铂类药物和顺铂放疗耐药的有效治疗方法。
Theranostics. 2021 Sep 21;11(19):9571-9586. doi: 10.7150/thno.61711. eCollection 2021.

引用本文的文献

1
SLC16A1 Inhibits Ferroptosis and Promotes the Progression of Head and Neck Squamous Cell Carcinoma.溶质载体家族16成员1(SLC16A1)抑制铁死亡并促进头颈部鳞状细胞癌进展。
J Cancer. 2025 Mar 29;16(7):2184-2196. doi: 10.7150/jca.110217. eCollection 2025.
2
VAV2 orchestrates the interplay between regenerative proliferation and ribogenesis in both keratinocytes and oral squamous cell carcinoma.VAV2在角质形成细胞和口腔鳞状细胞癌中协调再生增殖与核糖体生物合成之间的相互作用。
Sci Rep. 2024 Feb 19;14(1):4060. doi: 10.1038/s41598-024-54808-0.

本文引用的文献

1
The functional role of Pescadillo ribosomal biogenesis factor 1 in cancer.佩斯凯迪洛核糖体生物合成因子1在癌症中的功能作用。
J Cancer. 2022 Jan 1;13(1):268-277. doi: 10.7150/jca.58982. eCollection 2022.
2
Long Intergenic Non-Coding RNAs in HNSCC: From "Junk DNA" to Important Prognostic Factor.头颈部鳞状细胞癌中的长链基因间非编码RNA:从“垃圾DNA”到重要的预后因素
Cancers (Basel). 2021 Jun 12;13(12):2949. doi: 10.3390/cancers13122949.
3
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies.
复发性/转移性头颈部鳞状细胞癌:一个重大且引人关注的挑战,或许可通过局部区域治疗与全身治疗相结合的综合疗法得以解决。
Cancers (Basel). 2021 May 14;13(10):2371. doi: 10.3390/cancers13102371.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
PES1 In Liver Cancer: A Prognostic Biomarker With Tumorigenic Roles.PES1在肝癌中的作用:一种具有致瘤作用的预后生物标志物
Cancer Manag Res. 2019 Nov 14;11:9641-9653. doi: 10.2147/CMAR.S226471. eCollection 2019.
6
PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer.PES1 通过增加胰腺癌中 c-Myc 的表达促进 BET 抑制剂耐药和细胞增殖。
J Exp Clin Cancer Res. 2019 Nov 12;38(1):463. doi: 10.1186/s13046-019-1466-7.
7
The changing therapeutic landscape of head and neck cancer.头颈部癌症治疗领域的变化。
Nat Rev Clin Oncol. 2019 Nov;16(11):669-683. doi: 10.1038/s41571-019-0227-z. Epub 2019 Jun 12.
8
PES1 promotes the occurrence and development of papillary thyroid cancer by upregulating the ERα/ERβ protein ratio.PES1 通过上调 ERα/ERβ 蛋白比率促进甲状腺乳头状癌的发生和发展。
Sci Rep. 2019 Jan 31;9(1):1032. doi: 10.1038/s41598-018-37648-7.
9
PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway.PES1 通过 PI3K/AKT 通路促进肝癌的增殖和肿瘤发生。
Life Sci. 2019 Feb 15;219:182-189. doi: 10.1016/j.lfs.2018.12.054. Epub 2019 Jan 8.
10
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.诱导化疗(IC)加放疗(RT)与西妥昔单抗加 IC 和 RT 联合治疗仅可全喉切除术切除的晚期喉/下咽癌:DeLOS-II 喉器官保存试验的最终结果。
Ann Oncol. 2018 Oct 1;29(10):2105-2114. doi: 10.1093/annonc/mdy332.